Filing Details
- Accession Number:
- 0001104659-13-041519
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-05-14 17:34:13
- Reporting Period:
- 2013-05-14
- Filing Date:
- 2013-05-14
- Accepted Time:
- 2013-05-14 17:34:13
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1463729 | Receptos Inc. | RCPT | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1575852 | Lilly Ventures Fund I Llc | 10835 Road To The Cure, Suite 205 San Diego CA 92121 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2013-05-14 | 1,152,039 | $5.25 | 1,266,324 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2013-05-14 | 672,029 | $7.73 | 1,938,353 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2013-05-14 | 142,857 | $14.00 | 2,081,210 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2013-05-14 | 8,640,289 | $0.00 | 1,152,039 | $5.25 |
| Common Stock | Series B Preferred Stock | Disposition | 2013-05-14 | 5,040,221 | $0.00 | 672,029 | $7.73 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- The Series A preferred stock and Series B preferred stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of common stock for every 7.5 shares of Series A preferred stock and Series B preferred stock, for no additional consideration.
Billionaire Hedge Funds
